Mirabegron 50mg

DRUG5 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Samsung Medical Center, Dong-A ST Co., Ltd., University of Naples, Kafrelsheikh University

Conditions

AsthmaCirrhosisDry AMDHealthyHealthy VolunteersOveractive Bladder

Phase 1

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

CompletedNCT05992428

Dong-A ST Co., Ltd.Healthy

Start: 2023-08-22End: 2023-12-05Updated: 2024-01-25

Phase 2

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

CompletedNCT01950520

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Healthy Volunteers

Start: 2014-02-07End: 2024-06-11Updated: 2024-10-16

Phase 4

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

CompletedNCT02468375

Samsung Medical CenterOveractive Bladder

Start: 2015-06-30End: 2017-12-31Updated: 2018-02-28

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

CompletedNCT07533565

Kafrelsheikh UniversityAsthma, Cirrhosis

Start: 2024-07-01End: 2025-10-01Updated: 2026-04-16

Unknown Phase

Mirabegron in Patients With Age-Related Macular Degeneration

Not yet recruitingNCT07305298

University of NaplesDry AMD, Overactive Bladder

Start: 2026-04-01End: 2026-12-01Target: 312Updated: 2026-02-06

Related Papers

Mirabegron in patients with age-related macular degeneration treated for overactive bladder: a study protocol for a prospective observational non-randomized trial

Frontiers in Medicine2026-03-16